ViiV Healthcare is looking to investigate twice ... achieved high efficacy and was well tolerated through six months. “We’re looking forward to continuing the development of VH109 as a ...

LONDON, March 12, 2025--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two ...

LONDON, March 12, 2025--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced new data from two ...

These results were presented today at the Conference on Retroviruses and Opportunistic Infections (CROI 2025) in San Francisco, U.S. Kimberly Smith, M.D., MPH, Head of Research & Development at ViiV ...

London, 12 March 2025 – ViiV Healthcare, the global specialist HIV company majority owned by GSK ... No cases of HIV acquisition were observed through 12 months. Persistence on CAB LA was high, at 85% ...

ViiV Healthcare, the global specialist HIV company ... achieved high efficacy and was well tolerated through six months. We’re looking forward to continuing the development of VH109 as a ...

The EMBRACE study demonstrated that VH109, a CD4-binding broadly neutralising antibody, administered every four months with cabotegravir, achieved high efficacy and was well tolerated through six ...

Chief Medical Officer at ViiV Healthcare, said ... No cases of HIV acquisition were observed through 12 months. Persistence on CAB LA was high, at 85% (n=171/201) at six months and 72% (n ...

(RTTNews) - GSK plc (GSK)'s subsidiary ViiV Healthcare ... governments and other stakeholders to make APRETUDE available through public drug plans. Currently, GSK's stock is trading at $36. ...